5 news items
Aurinia Addresses Dubious Proposals Put Forth by Lucien Selce
AUPH
4 Jun 24
be found in Aurinia's most recent Annual Report on Form 10-K and its other public available filings available by accessing the Canadian Securities
Analysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation's Spring Clinical Meeting 2024
AUPH
14 May 24
patients.
"People living with lupus nephritis must be able to access clinically meaningful treatment
Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results
AUPH
2 May 24
will be accessible on Aurinia's website
Aurinia Underscores Enduring Commitment to People Living with Lupus Nephritis Through Innovative Advocacy and Education Initiatives for Lupus Awareness Month
AUPH
1 May 24
to access, promote equity, and improve health outcomes for those impacted by LN.
"Since its inception, Aurinia
Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024
AUPH
15 Apr 24
U.S. & Canada). The audio webcast can also be accessed
- Prev
- 1
- Next